Cara Therapeutics (NASDAQ:CARA – Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
Profitability
This table compares Cara Therapeutics and 60 Degrees Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cara Therapeutics | -1,010.20% | -241.31% | -110.04% |
| 60 Degrees Pharmaceuticals | N/A | N/A | -98.31% |
Analyst Recommendations
This is a breakdown of recent ratings for Cara Therapeutics and 60 Degrees Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cara Therapeutics | 0 | 5 | 0 | 0 | 2.00 |
| 60 Degrees Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Insider and Institutional Ownership
44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by insiders. Comparatively, 10.3% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Cara Therapeutics and 60 Degrees Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cara Therapeutics | $20.97 million | 0.86 | -$118.51 million | ($2.04) | -0.16 |
| 60 Degrees Pharmaceuticals | $250,000.00 | 7.07 | -$3.77 million | $0.09 | 10.36 |
60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Cara Therapeutics. Cara Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Cara Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 4.78, meaning that its stock price is 378% more volatile than the S&P 500.
Summary
60 Degrees Pharmaceuticals beats Cara Therapeutics on 9 of the 12 factors compared between the two stocks.
About Cara Therapeutics
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
